COVID-19: PHARMACOLOGICAL AND THERAPEUTIC APPROACHES

Mai ES. Ghoneim; Bassma M. Ali; Asmaa A. Khalifa

doi:10.22270/ujpr.v5i6.514

Mai ES. Ghoneim Faculty of Pharmacy, University of Sadat City, Menofia, Egypt.
Bassma M. Ali Arab Academy for Sciences and Technology and Maritime Transport, Alexandria, Egypt.
Asmaa A. Khalifa Faculty of Pharmacy, Pharos University, Alexandria, Egypt.

10.22270/ujpr.v5i6.514

Keywords:

Favipiravir, Monoclonal antibodies, Pathophysiology, Remdesivir, SARS-COV-2

Abstract

In the end of 2019, SARS-CoV-2, a new virus from Corona viruses family, has been detected in China and was responsible for COVID-19 disease. This disease has been suddenly and vigorously disseminated among individuals all over the world. Based on genetic vicinity, this novel virus is similar to SARS-CoV and MERS-CoV and it can spread from an unknown animal host to individuals. Many published clinical data and in vitro studies may offer treatment strategies of some effective antiviral and repurposed drugs, including remdesivir, favipiravir, lopinavir/ritonavir, corticosteroids, etc. This narrative review describes current pharmacological proposed treatments for COVID-19 patients and available experimental and clinical studies for these drugs. Eventually, these data may help to explain the most preferable way to treat COVID-19 and lessen the accompanied symptoms and complications.